Addressing Gaps in Secondary Stroke Prevention With Factor XIa Inhibition

In this solo episode of the Tell-Tale Heart podcast, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, reviews emerging phase 3 data on factor XIa inhibition as a potential approach to secondary stroke prevention. Beavers discusses results from the phase 3 OCEANIC-STROKE trial (NCT05686070), which demonstrated reduced recurrent ischemic stroke and cardiovascular events in patients with noncardioembolic stroke or high-risk transient ischemic attack without an increase in major bleeding. Beavers underscores the importance of patient selection and highlighted how novel antithrombotic strategies may expand future options for pharmacists involved in cardiovascular and stroke care as additional data and regulatory decisions emerge.

Tune in for an insightful discussion.